<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Angiotensin-converting enzyme (ACE) inhibitors and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-receptor blockers (ARBs) are prototypes of "upstream" therapy for the management of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>Ectopic activity arising from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> sleeves plays a prominent role in the development of AF </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Transmembrane action potentials were recorded from canine superfused left superior or inferior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> sleeves using standard microelectrode techniques </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="9" ids="15355">Acetylcholine</z:chebi> (<z:chebi fb="0" ids="15355">ACh</z:chebi>, 1 μM), <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> (1 μM), high calcium ([Ca(2+)](o) = 5.4 mM) or a combination was used to induce early or delayed afterdepolarizations (EADs or DADs) and triggered activity </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The ARB <z:chebi fb="0" ids="6541">losartan</z:chebi> (1 μM, n = 5) and the <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> enalapril (10 μM, n = 5) produced no significant change in action potential duration, maximum rate of rise of action potential upstroke (V(max)), action potential amplitude or take-off potential at basic cycle lengths of 200 to 2000 ms </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> (1 μM) and enalapril (10-20 μM) markedly attenuated or suppressed EADs and DAD-induced triggered activity elicited by exposure of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> sleeves to <z:chebi fb="0" ids="15355">ACh</z:chebi>, <z:chebi fb="0" ids="6046">isoproterenol</z:chebi> or high calcium following rapid pacing in 6 of 6 (<z:chebi fb="0" ids="6541">losartan</z:chebi>) and 4 of 5 (enalapril) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> sleeve preparations </plain></SENT>
<SENT sid="6" pm="."><plain>Neither <z:chebi fb="0" ids="6541">losartan</z:chebi> nor enalapril altered Ca(2+) or <z:chebi fb="0" ids="29103">K(+)</z:chebi> channel currents in enzymatically-dissociated atrial myocytes at these concentrations </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our data suggest that in addition to their "upstream" effects to reduce atrial structural remodeling, <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> and ARBs exert a "direct" antiarrhythmic effect by suppressing triggers responsible for the genesis of AF and other atrial <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
</text></document>